Clinical Trials Logo

Recurrent Melanoma clinical trials

View clinical trials related to Recurrent Melanoma.

Filter by:

NCT ID: NCT03220009 Not yet recruiting - Recurrent Melanoma Clinical Trials

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Start date: November 3, 2017
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well nivolumab or expectant observation following ipilimumab, nivolumab, and surgery work in treating patients with high-risk mucosal melanoma that is restricted to the site of origin without evidence of spread, has spread to a local and regional area of the body, or has come back. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread. Sometimes the mucosal melanoma may not need more treatment until it progresses. In this case, observation may be sufficient. It is not known if nivolumab or expectant observation following ipilimumab, nivolumab, and surgery may be better in treating patients with mucosal melanoma.

NCT ID: NCT03050060 Recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

Start date: June 9, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well image guided hypofractionated radiation therapy works with nelfinavir mesylate and nivolumab in treating patients with melanoma, lung cancer, or kidney cancer that has spread. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving hypofractionated radiation therapy, nelfinavir mesylate, and nivolumab may work better in treating patients with melanoma, lung, or kidney cancer.

NCT ID: NCT02965716 Not yet recruiting - Recurrent Melanoma Clinical Trials

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Start date: August 4, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well talimogene laherparepvec and pembrolizumab work in treating patients with stage III-IV melanoma. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and pembrolizumab may work better in treating patients with melanoma by shrinking the tumor.

NCT ID: NCT02507076 Withdrawn - Recurrent Melanoma Clinical Trials

Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma

Start date: April 2012
Phase: N/A
Study type: Interventional

This pilot clinical trial studies isolated limb perfusion with melphalan in treating patients with stage IIIB-IV melanoma or sarcoma. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Heating a chemotherapy solution and infusing it directly into the arteries around the tumor may kill more tumor cells.

NCT ID: NCT02465060 Recruiting - Lymphoma Clinical Trials

NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

Start date: August 12, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

NCT ID: NCT02304458 Recruiting - Metastatic Melanoma Clinical Trials

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Start date: February 2, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas that have come back (recurrent) or do not respond to treatment (refractory). Monoclonal antibodies, such as nivolumab and ipilimumab, may block tumor growth in different ways by targeting certain cells. It is not yet known whether nivolumab works better alone or with ipilimumab in treating patients with recurrent or refractory solid tumors or sarcomas.

NCT ID: NCT02298959 Recruiting - Metastatic Melanoma Clinical Trials

Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors

Start date: March 13, 2015
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of ziv-aflibercept when given together with pembrolizumab in treating patients with solid tumors that have spread to other places in the body. Ziv-afibercept works by decreasing blood and nutrient supply to the tumor, which may result in shrinking the tumor. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving ziv-aflibercept together with pembrolizumab may be a better treatment for patients with advanced solid tumors.

NCT ID: NCT02296112 Recruiting - Recurrent Melanoma Clinical Trials

Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations

Start date: January 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies trametinib in treating patients with melanoma with v-Raf murine sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other places in the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02263898 Withdrawn - Recurrent Melanoma Clinical Trials

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Start date: January 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies intermittent dosing of BRAF inhibitor LGX818 (encorafenib) and MEK inhibitor MEK 162 (binimetinib) in treating patients with melanoma that has spread to other parts of the body (metastatic) and have a BRAF V600 mutation. LGX818 and MEK162 may stop the growth of tumor cells by blocking different enzymes needed for cell growth. Giving LGX818 and MEK162 with breaks between each course (intermittently) may help delay the time when tumors become resistant to the drugs.

NCT ID: NCT02236546 Terminated - Recurrent Melanoma Clinical Trials

FDG-PET in Advanced Melanoma

Start date: May 2012
Phase: N/A
Study type: Interventional

This clinical trial studies how well FDG-PET/CT measures early response in patients with stage III-IV melanoma who are receiving chemotherapy. Positron emission tomography (PET)/computed tomography (CT) uses a metabolic imaging radiotracer, [18F]fluorodeoxyglucose (FDG), which selectively accumulates in tumors. FDG-PET/CT of advanced melanoma before, during, and after treatment may improve methods for predicting which patients may benefit from therapy.